[First-line treatment of lymphomas of "high grade malignancy" or "aggressive lymphomas"].
Main strategies used as first line treatment of aggressive lymphoma are the subject of this review. The evolution of histopathlogical classifications is reviewed and the concept of aggressive lymphoma is given. General principles of chemotherapy treatment and main prognostic factors that direct therapeutic decisions are described. The treatment modalities of localized and advanced disease are detailed, as well as the role of high-dose therapy with hematopoietic support. Finally, the major impact of immunotherapy based on the monoclonal anti-CD20 antibody is envisaged.
Reyes
F
F
Service d'hématologie clinique, centre hospitalier universitaire Henri Mondor et groupe d'études des lymphomes agressifs (Gela), 94010 Créteil, France. felix.reyes@hmn.ap-hop-paris.fr
D000906:Antibodies / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis
D000906:Antibodies; D018951:Antigens, CD20